AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05858008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
Study NCT04256954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Description: A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
Study NCT04898634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: JNJ-78278343 will be administered.
Study NCT06544616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64042056
Description: JNJ-64042056 will be administered intramuscularly.
Study NCT06544616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intramuscularly.
Study NCT04533750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT04533750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT04533750 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04533750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04533750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study NCT04533750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06340360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study NCT06340360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study NCT05055063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
Study NCT06039176 — intervention group
Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
Study NCT04886219 — intervention group
Intervention type: OTHER
Intervention: Eye examination
Description: * Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~* orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~* ocular biometry~* corneal topography~* monocular photographs in photopic and scotopic condition
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Patient Education
Description: In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment to Change
Description: Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring
Description: Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Patient Education
Description: Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-based reinforcement for CKD self-management
Description: Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based education session, reinforcement for self-management
Description: Patient educator will use provide a booster session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
Study NCT06397456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text-based reinforcement for general health self-management
Description: Patient educator will use text messages to send general health management messages
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV020 (SAR445088)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous immunoglobulin (IVIg)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab or biosimilar
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab or biosimilar
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical Form: Tablet Route of Administration: Oral
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: Pharmaceutical Form: Tablet Route of Administration: Oral
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Pharmaceutical Form: Vary Route of Administration: Vary
Study NCT05156710 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroids
Description: Pharmaceutical Form: Vary Route of Administration: Vary
Study NCT06475521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Test group
Study NCT06475521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: Test group
Study NCT04434664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate
Description: The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
Study NCT04434664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
Study NCT05472909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Relaxation Music
Description: Participants listen to standardized relaxation music during surgery.
Study NCT05472909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal Choice of Music
Description: Participants listen to their preferred music during surgery.
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-TLX591
Description: Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
Study NCT06500065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo dPET/CT
Study NCT06500065 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-HA-DOTA-TATE
Description: Given IV
Study NCT06500065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo dPET/CT
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
Study NCT06520345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
Study NCT06410950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MyotonPRO Assessment of Muscle Biomechanical Properties
Description: Muscle assessments will be conducted using the MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. Measurement patterns and subject data will be uploaded to the device via computer. Each evaluation will be performed bilaterally.~Subjects' muscle measurement points will be marked prior to assessment. The physiotherapist will position the device perpendicular to the muscle body and apply downward pressure (18N). Pressure should be maintained until the device's probe light changes from red to green. Five measurement pulses will then be applied. Each pulse lasts 15 ms with an 8 ms interval between pulses.~The SENIAM sensor location guide will be used to determine the approximate motor point for MyotonPRO measurements.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: ISL capsule taken by mouth.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Ulonivirine tablet taken by mouth.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: BIC/FTC/TAF tablet taken by mouth.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ISL
Description: Placebo capsule matched to ISL taken by mouth.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ulonivirine
Description: Placebo tablet matched to ulonivirine taken by mouth.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ulonivirine
Description: Placebo tablet matched to ulonivirine taken by mouth.
Study NCT04564547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.
Study NCT05525936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography and central venous pressure
Description: To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
Study NCT06397027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Given by IV
Study NCT06397027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT06397027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by PO
Study NCT06007274 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05279235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
Study NCT05279235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JT001 placebo
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
Study NCT05279235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
Study NCT06505499 — intervention group
Intervention type: OTHER
Intervention: Gait Profile Score
Description: Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009).
Study NCT06505499 — intervention group
Intervention type: OTHER
Intervention: Gait Visual Score
Description: Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009)
Study NCT05378100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Infusion of ketamine 0.5 mg/kg over 40 minutes
Study NCT05279235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir placebo
Description: Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
Study NCT05378100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Infusion of midazolam 0.05 mg/kg over 40 minutes
Study NCT05204797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted UKA
Description: Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.
Study NCT05204797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique UKA
Description: Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
Study NCT04518917 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mentally Singing
Description: Participants sing their song in their head and match their footfalls to the beat.
Study NCT04518917 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Listening to music
Description: Participants listen to their song and match their footfalls to the beat.
Study NCT04266418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 2 months
Study NCT04266418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Banana flower stamens extract
Description: consume 1 sachet per day for 2 months
Study NCT06218602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Given by PO
Study NCT06218602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given by Infusion
Study NCT06218602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: Given by Infusion
Study NCT05099302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: divert attention
Description: In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
Study NCT04983043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose QiShen YiQi Dripping Pills 3 bags
Description: Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Study NCT04983043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose QiShen YiQi Dripping Pills 3 bags
Description: High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
Study NCT04983043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QiShen YiQi Dripping Pills placebo 3 bags
Description: QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Study NCT05144698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-201 Rapamycin Resistant T Cells
Description: Autologous Rapamycin-Resistant Th1/Tc1 Cells
Study NCT05144698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Prior to RAPA-201 Therapy
Description: Carboplatin + Paclitaxel Regimen (CP Regimen)
Study NCT06359951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project YES
Description: Digital SSI
Study NCT05160272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-325
Description: Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
Study NCT05160272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching AP-325
Description: Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
Study NCT05410496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
Study NCT05528510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab (Dose 1) will be administered as SC injection.
Study NCT05528510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab (Dose 2) will be administered as SC injection.
Study NCT05528510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Guselkumab (Dose 3) will be administered as SC injection.
Study NCT05528510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as SC injection.
Study NCT05483933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin + SL-172154
Description: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study NCT05483933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab + SL-172154
Description: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study NCT05283980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Description: The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
Study NCT05283980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
Study NCT04286789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ORTD-1
Description: Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
Study NCT04286789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose vehicle control
Description: Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
Study NCT04286789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ORTD-1
Description: Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
Study NCT04286789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High dose vehicle control
Description: Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
Study NCT06647810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 1
Description: BI 690517 formulation 1
Study NCT06647810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 2
Description: BI 690517 formulation 2
Study NCT06647810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid